Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug
failure also with very effective drugs (ie, secukinumab) and, consequently, dermatologists …

Background There are limited data regarding the long‐term continuation with biological
therapy for patients with psoriasis. In particular, the reasons for secukinumab discontinuation …

Background: The efficacy and safety of secukinumab in patients with plaque psoriasis (PsO)
have been demonstrated in randomized clinical trials (RCTs). However, data regarding its …

To evaluate drug survival of secukinumab in a daily practice setting, we retrospectively
evaluated all psoriatic patients starting secukinumab during January 2016-February 2017 at …

Introduction There is limited and conflicting evidence over the real-world drug survival of
secukinumab (SEC) in patients with psoriasis, especially in the long term. Our objective was …

Background Long-term real-life data on secukinumab use in psoriasis are limited. Objectives
Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in …

Background: Long term data on the real-life use of secukinumab are scant. The aim of this
study was to investigate the real-life effectiveness, safety and treatment persistence of …

Background Psoriasis is a chronic systemic disease that requires long‐term management.
Despite data on follow‐up studies going back 5 years, little is known about the condition's …

Background Secukinumab is effective against a range of psoriatic manifestations.
Investigating psoriasis (PsO) relapse following secukinumab discontinuation could provide …

Background Secukinumab has demonstrated significant efficacy with a good safety profile
through 1 year in plaque psoriasis. Given the chronic nature of this disease, long‐term follow …